Decoy Therapeutics
DCOY
3 hedge funds and large institutions have $29.5M invested in Decoy Therapeutics in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
40% less funds holding
Funds holding: 5 → 3 (-2)
58% less capital invested
Capital invested by funds: $70.8M → $29.5M (-$41.2M)
83% less call options, than puts
Call options by funds: $9K | Put options by funds: $53K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$6.1M |
| 2 |
Jennison Associates
New York
|
-$6.1M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$1.67M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.44M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$598K |
DCOY Hedge Fund Activity: Q4 2016 in Review
3 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q4 2016, worth a combined $29.5M — down 58% from $70.8M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DCOY and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock Fund Advisors, exiting entirely with an estimated $6.1M sold.
- 3 institutional investors held Decoy Therapeutics (DCOY) as of Q4 2016, down from 5 in Q3 2016.
- Funds reported $29.5M of Decoy Therapeutics stock for Q4 2016, down 58% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q4 2016 and 2 closed out, a net change of -2 holders.
- The largest Decoy Therapeutics seller in Q4 2016 was BlackRock Fund Advisors, an estimated $6.1M sold.
Based on aggregated 13F filings for Q4 2016.